Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MB | P02144 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | RARG | P13631 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959278 | 0.83 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL5026270 | 0.83 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL861674 | 0.82 | SMN1; SMN2 (0.84) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL3074944 | 0.81 | ALDH1A1 (0.70) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL1488124 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL19672881 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL5026275 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL21291520 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL20850583 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTL3MBTL1GAAKMT2A | |
| SCHEMBL9713055 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTL3MBTL1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030130-B2 | Benzofuran derivatives and their use as antibacterial agents | ARPIDA AG (CH) | 2006-04-18 | — | — | US | claimed |
| EP-1307445-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2005-12-21 | — | — | EP | claimed |
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | EVOLVA SA (CH) | 2004-02-19 | — | — | US | claimed |
| EP-1307445-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Arpida AG, (CH) | 2003-05-07 | — | — | EP | claimed |
| WO-2002010157-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | claimed |
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-7030130-B2 | Benzofuran derivatives and their use as antibacterial agents | ARPIDA AG (CH) | 2006-04-18 | — | — | US | disclosed |
| EP-1307445-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | EVOLVA SA (CH) | 2004-02-19 | — | — | US | disclosed |
| EP-1307445-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Arpida AG, (CH) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010157-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| EP-0832100-B1 | NOVEL INHIBITORS OF METALLOPROTEASES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | AFFYMAX TECH NV (AN) | 2000-04-05 | — | — | EP | disclosed |
| US-5929278-A | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use | AFFYMAX TECHNOLOGIES N.V. (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5840698-A | ENZYME INHIBITORS OF MERCAPTOKETONES AND MERCAPTOALCOHOLS FOR CONTROLLING DISEASES OF TISSUE BREAKDOWN, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS OR ANTITUMOR AGENTS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1998-11-24 | — | — | US | disclosed |
| US-5831004-A | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use | AFFYMAX TECHNOLOGIES N.V. (GB) | 1998-11-03 | — | — | US | disclosed |
| EP-0832100-A4 | NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECH NV (AN) | 1998-09-02 | — | — | EP | disclosed |
| EP-0832100-A1 | NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECHNOLOGIES N.V. (AN) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040204-A1 | NOVEL INHIBITORS OF COLLAGENASE-1 AND STROMELYSIN-I METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECHNOLOGIES, N.V. (AN) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040738-A1 | NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECHNOLOGIES, N.V. (AN) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | SBDS, BPTF, DCXR | SMN1; SMN2 3686/4885HTT 3152/4885L3MBTL1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.